Abstract
AimThis study aimed at comparing two statistical approaches to analyze the effect of Botulinum Toxin A (BTX-A) treatment on gait in children with a diagnosis of spastic cerebral palsy (CP), based on three-dimensional gait analysis (3DGA) data. Through a literature review, the available expert knowledge on gait changes after BTX-A treatment in children with CP is summarized.MethodsPart 1—Intervention studies on BTX-A treatment in children with CP between 4–18 years that used 3DGA data as an outcome measure and were written in English, were identified through a broad systematic literature search. Reported kinematic and kinetic gait features were extracted from the identified studies. Part 2—A retrospective sample of 53 children with CP (6.1 ± 2.3years, GMFCS I-III) received 3DGA before and after multilevel BTX-A injections. The effect of BTX-A on gait was interpreted by comparing the results of paired samples t-tests on the kinematic gait features that were identified from literature to the results of statistical parametric mapping analysis on the kinematic waveforms of the lower limb joints.ResultsPart 1–53 kinematic and 33 kinetic features were described in literature. Overall, there is no consensus on which features should be evaluated after BTX-A treatment as 49 features were reported only once or twice. Part 2—Post-BTX-A, both statistical approaches found increased ankle dorsiflexion throughout the gait cycle. Statistical parametric mapping analyses additionally found increased knee extension during terminal stance. In turn, feature analyses found increased outtoeing during stance after BTX-A.ConclusionThis study confirms that BTX-A injections are a valuable treatment option to improve gait function in children with CP. However, different statistical approaches may lead to different interpretations of treatment outcome. We suggest that a clear, definite hypothesis should be stated a priori and a commensurate statistical approach should accompany this hypothesis.
Highlights
Pathological gait is one of the most striking characteristics in children with cerebral palsy (CP) [1]
The effect of Botulinum toxin A (BTX-A) on gait was interpreted by comparing the results of paired samples t-tests on the kinematic gait features that were identified from literature to the results of statistical parametric mapping analysis on the kinematic waveforms of the lower limb joints
There is no consensus on which features should be evaluated after BTX-A treatment as 49 features were reported only once or twice
Summary
Pathological gait is one of the most striking characteristics in children with cerebral palsy (CP) [1]. There is a wide variety of treatments which can be applied to improve gait, ranging from conservative treatments such as physiotherapy, orthotics, and Botulinum toxin A (BTX-A) injections to surgical interventions such as single event multilevel surgery and selective dorsal rhizotomy. Depending on a patient’s symptoms and age, different treatment modalities might be appropriate. Gait changes after treatment are often objectively quantified by using three-dimensional gait analysis (3DGA). Researchers and clinicians are challenged to extract and analyze the clinically relevant information from this large amount of data
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have